CRL vs BIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 02, 2026

CRL

50.6
AI Score
VS
BIO Wins

BIO

54.3
AI Score

Investment Advisor Scores

CRL

51score
Recommendation
HOLD

BIO

54score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CRL BIO Winner
Revenue 592.10M 995.83M CRL
Net Income -527.10M -14.84M CRL
Net Margin -89.0% -1.5% CRL
Operating Income 34.10M 119.90M CRL
ROE -7.7% -0.5% CRL
ROA -5.4% -0.2% CRL
Total Assets 9.79B 7.73B BIO
Cash 507.20M 191.83M BIO
Current Ratio 3.21 1.36 BIO

Relative Price Performance (Last 90 Days)

CRL 1M: +1.5% · 3M: +39.3% BIO 1M: +9.6% · 3M: +16.2%

Current Technical Phase

CRL

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (13.4% over 20 days), RSI 60

RSI (14): 59.9 · Price: $232.51

BIO

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (5.7% over 20 days), RSI 67

RSI (14): 66.6 · Price: $325.48

Fundamentals Snapshot

Metric CRL BIO
Market Cap
Forward P/E 18.9 33.5
Trailing P/E 54.4
Revenue (TTM)
Revenue Growth 0.0% 0.0%
Gross Margin 0.3% 0.5%
Operating Margin 0.2% 0.1%
EPS -3.71 6.01
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, BIO is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.